These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 32167135)

  • 21. Contribution of GTPase activity to LRRK2-associated Parkinson disease.
    Tsika E; Moore DJ
    Small GTPases; 2013; 4(3):164-70. PubMed ID: 24025585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2.
    Biosa A; Trancikova A; Civiero L; Glauser L; Bubacco L; Greggio E; Moore DJ
    Hum Mol Genet; 2013 Mar; 22(6):1140-56. PubMed ID: 23241358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allosteric inhibition of LRRK2, where are we now.
    Soliman A; Cankara FN; Kortholt A
    Biochem Soc Trans; 2020 Oct; 48(5):2185-2194. PubMed ID: 33079169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First model of dimeric LRRK2: the challenge of unrevealing the structure of a multidomain Parkinson's-associated protein.
    Guaitoli G; Gilsbach BK; Raimondi F; Gloeckner CJ
    Biochem Soc Trans; 2016 Dec; 44(6):1635-1641. PubMed ID: 27913672
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The R1441C mutation of LRRK2 disrupts GTP hydrolysis.
    Lewis PA; Greggio E; Beilina A; Jain S; Baker A; Cookson MR
    Biochem Biophys Res Commun; 2007 Jun; 357(3):668-71. PubMed ID: 17442267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure and nucleotide-induced conformational dynamics of the
    Deyaert E; Leemans M; Singh RK; Gallardo R; Steyaert J; Kortholt A; Lauer J; Versées W
    Biochem J; 2019 Jan; 476(1):51-66. PubMed ID: 30538153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The unconventional G-protein cycle of LRRK2 and Roco proteins.
    Terheyden S; Nederveen-Schippers LM; Kortholt A
    Biochem Soc Trans; 2016 Dec; 44(6):1611-1616. PubMed ID: 27913669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.
    Stafa K; Trancikova A; Webber PJ; Glauser L; West AB; Moore DJ
    PLoS Genet; 2012; 8(2):e1002526. PubMed ID: 22363216
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Parkinson disease gene LRRK2: evolutionary and structural insights.
    Marín I
    Mol Biol Evol; 2006 Dec; 23(12):2423-33. PubMed ID: 16966681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parkinson disease-associated mutation R1441H in LRRK2 prolongs the "active state" of its GTPase domain.
    Liao J; Wu CX; Burlak C; Zhang S; Sahm H; Wang M; Zhang ZY; Vogel KW; Federici M; Riddle SM; Nichols RJ; Liu D; Cookson MR; Stone TA; Hoang QQ
    Proc Natl Acad Sci U S A; 2014 Mar; 111(11):4055-60. PubMed ID: 24591621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LRRK2 Targeting Strategies as Potential Treatment of Parkinson's Disease.
    Wojewska DN; Kortholt A
    Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The dual enzyme LRRK2 hydrolyzes GTP in both its GTPase and kinase domains in vitro.
    Liu Z; West AB
    Biochim Biophys Acta Proteins Proteom; 2017 Mar; 1865(3):274-280. PubMed ID: 27939437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kinase activity of mutant LRRK2 manifests differently in hetero-dimeric vs. homo-dimeric complexes.
    Leandrou E; Markidi E; Memou A; Melachroinou K; Greggio E; Rideout HJ
    Biochem J; 2019 Feb; 476(3):559-579. PubMed ID: 30670570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biochemical and kinetic properties of the complex Roco G-protein cycle.
    Wauters L; Terheyden S; Gilsbach BK; Leemans M; Athanasopoulos PS; Guaitoli G; Wittinghofer A; Gloeckner CJ; Versées W; Kortholt A
    Biol Chem; 2018 Nov; 399(12):1447-1456. PubMed ID: 30067506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Leucine-rich repeat kinase 2: relevance to Parkinson's disease.
    Guo L; Wang W; Chen SG
    Int J Biochem Cell Biol; 2006; 38(9):1469-75. PubMed ID: 16600664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LRRK2 autophosphorylation enhances its GTPase activity.
    Liu Z; Mobley JA; DeLucas LJ; Kahn RA; West AB
    FASEB J; 2016 Jan; 30(1):336-47. PubMed ID: 26396237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Roc, the G-domain of the Parkinson's disease-associated protein LRRK2.
    Park Y; Liao J; Hoang QQ
    Trends Biochem Sci; 2022 Dec; 47(12):1038-1047. PubMed ID: 35840518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites.
    Greggio E; Taymans JM; Zhen EY; Ryder J; Vancraenenbroeck R; Beilina A; Sun P; Deng J; Jaffe H; Baekelandt V; Merchant K; Cookson MR
    Biochem Biophys Res Commun; 2009 Nov; 389(3):449-54. PubMed ID: 19733152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant.
    Daniëls V; Vancraenenbroeck R; Law BM; Greggio E; Lobbestael E; Gao F; De Maeyer M; Cookson MR; Harvey K; Baekelandt V; Taymans JM
    J Neurochem; 2011 Jan; 116(2):304-15. PubMed ID: 21073465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural model of the dimeric Parkinson's protein LRRK2 reveals a compact architecture involving distant interdomain contacts.
    Guaitoli G; Raimondi F; Gilsbach BK; Gómez-Llorente Y; Deyaert E; Renzi F; Li X; Schaffner A; Jagtap PK; Boldt K; von Zweydorf F; Gotthardt K; Lorimer DD; Yue Z; Burgin A; Janjic N; Sattler M; Versées W; Ueffing M; Ubarretxena-Belandia I; Kortholt A; Gloeckner CJ
    Proc Natl Acad Sci U S A; 2016 Jul; 113(30):E4357-66. PubMed ID: 27357661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.